The global hyperlipidemia prescription drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Hyperlipidemia is termed as excessive building up of abnormal amounts of fats or lipids in the blood. The two common forms of lipids found in the blood include triglycerides and cholesterol. People with abnormal or unhealthy levels of blood cholesterol have a more prominent risk of developing heart ailments such as plaque and other heart diseases. Globally, almost 15 million people suffer from heart attacks or similar issues, according to the World Heart Federation. Between 2016 and 2017, the US spent $363 billion on heart disease. The most frequent type of heart illness, coronary heart disease, affects approximately 18.2 million persons aged 20 and up (about 6.7%). These estimates of heart ailments lead to an increased demand for effective solutions such as hyperlipidemia prescription drugs, thereby augmenting the global hyperlipidemia prescription drugs market.

As stated by the World Health Organization (WHO), within the European Union leading economies such as Germany, Spain, Italy, France, and the UK, 133 million individuals experience the ill effects of terrible cholesterol. The commonly advised hyperlipidemia prescription drugs include statins, such as simvastatin, atorvastatin, lovastatin, and rosuvastatin. In addition to this, various new solutions such as PCSK9 inhibitors are being analyzed for individuals with a cardiovascular ailment that require a major dropping down of their LDL (low-density lipoprotein), sometimes known as bad cholesterol. Although in some cases, statins are not endured, owing to the reactions of muscle pain, individuals quit taking them. This factor may restrain the global hyperlipidemia prescription drugs market. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Drug Class
• By Application

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Amgen Inc., Eli Lilly & Co., and Daiichi Sankyo Co., Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
• o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hyperlipidemia Prescription Drugs Market Report by Segment

By Drug Class

• HMG COA Reductase Inhibitors
• Fibric Acid Derivatives 
• Nicotinic Acids
• Bile Acid Sequestrating Agents
• Cholesterol Absorption Inhibitors
• Others

By Application

• Hospitals
• Clinics

Global Hyperlipidemia Prescription Drugs Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa